First Analysis assumed coverage on shares of Athersys Inc (NASDAQ:ATHX) in a report issued. The firm issued an overweight rating and a $5.00 target price on the stock. Athersys, Inc. (NASDAQ:ATHX) stock opened at $1.44 in last session, and closed at $1.63, while the day range of ATHX stock is $1.40 – $1.67. The stock showed a negative weekly performance of -40.29%.
Acadia Healthcare Company Inc (NASDAQ:ACHC) reported first-quarter net income of $13.06 million or $0.26 per share, higher than $3.74 million, or $0.07 per share in the prior-year quarter. Adjusted income from continuing operations was $14.01 million or $0.28 per share for the quarter. Looking ahead to fiscal 2014, Acadia reaffirmed its guidance for adjusted earnings in the range of $1.26 to $1.29 per share. Analysts expect the company to report fiscal 2014 earnings of $1.31 per share. Acadia Healthcare Company Inc (NASDAQ:ACHC) stock opened at $41.49, in last session and closed at $44.98, by gaining 8.49%. The 52 week range of is $30.70 – $. Company’s market capitalization is $2.25billion.
Aastrom Biosciences Inc (NASDAQ:ASTM) entered into a definitive agreement to acquire Sanofi’s Cell Therapy & Regenerative Medicine (CTRM) business (currently operating under Genzyme A/S) for a purchase price of $6.5 million or 0.1x LTM revenues. Through the deal, Aastrom Biosciences Inc (NASDAQ:ASTM) acquires the global commercial rights to three marketed autologous cell therapy products: 1) Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant (ACI) intended for the treatment of articular cartilage defects; 2) Epicel (cultured epidermal autografts), a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area; and 3) MACI (matrix-induced autologous chondrocyte implant) a third-generation ACI product. Aastrom Biosciences Inc (NASDAQ:ASTM) stock advanced 5.79% and finished the last session at $4.20. The EPS of the stock remained -6.83. Company’s market capitalization is $25.99million.
Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced its financial results for the fiscal year ended December 31, 2013. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) stock opened the session at $1.66, and closed the session at $1.75. The 52 week range of the stock remained $0.62 – $3.49 and the day range was $1.65 – $1.77.